# Critical Evaluation of Legacy Pre-Pipeline Hypotheses
## General Methodological Concerns (Cross-Cutting Issues)
Before evaluating individual hypotheses, several systemic weaknesses affect the entire corpus:
**1. Animal Model Validity Crisis**
All seven hypotheses rely heavily on transgenic mouse models (5xFAD, MPTP, α-syn transgenic mice) with well-documented limitations:
- Mouse neuroimmune systems differ substantially from humans
- Accelerated pathology timelines may not reflect human disease etiology
- Many therapeutic candidates successful in rodents have failed in human trials (anti-Aβ antibodies, γ-secretase inhibitors)
**2. Publication Bias and Reproducibility**
Pre-2026 hypotheses are susceptible to positive-outcome publication bias. The field's history includes high-profile retracted papers and studies that couldn't be replicated (e.g., many α-syn propagation studies).
**3. Correlation vs. Causation**
Most supporting evidence demonstrates association (elevated protein X correlates with disease), not causation (manipulating X prevents or reverses disease).
---
## Hypothesis 1: Exosomal α-Synuclein Propagation
### Weak Links
| Component | Weakness |
|-----------|----------|
| **Mechanistic chain** | No direct demonstration that exosomal aSyn causes *de novo* aggregation in vivo rather than being a secondary clearance mechanism |
| **GWAS targets** | RAB27A, GBA, LRRK2 are associated with PD risk but mechanistically linked to multiple pathways; their specific role in exosome-mediated propagation is inferred |
| **Braak staging** | Retrograde transport explains some propagation patterns, but not all (e.g., peripheral-first theories, cardiac sympathetic involvement) |
### Counter-Evidence
1. **Exosome contamination problem**: CSF exosome isolation protocols produce heterogeneous preparations; distinguishing neuron-derived exosomes from astrocyte/microglia-derived vesicles is technically challenging and may confound interpretation.
2. **Alternative propagation mechanisms**: Cell-to-cell transfer can occur via tunneling nanotubes, direct cell fusion, and free aggregate release—exosomes may be one of multiple vectors or even a protective clearance mechanism.
3. **Negative replication studies**: Some laboratories have failed to consistently detect aSyn in CSF exosomes using sensitive assays, suggesting either low abundance or technical false negatives.
4. **LRRK2 complexity**: LRRK2 G2019S mutations enhance exosome release in some studies but not others, and LRRK2 inhibitors (which reduce exosome release) have not demonstrated anti-PD efficacy in clinical trials.
### Falsifying Experiments
1. **Block exosome release and test propagation**: Use GW4869 or dominant-negative VAMP7 to block exosome secretion in primary neuron cultures or in vivo; if aSyn aggregates still propagate between neurons via alternative mechanisms (tunneling nanotubes), the exosome hypothesis is insufficient.
2. **Isotopic labeling transfer**: Pre-label donor neurons with non-radioactive heavy isotopes (SILAC or 15N); detect transferred aSyn in recipient neurons by mass spectrometry rather than antibody-based methods to rule out antibody cross-reactivity.
3. **Human tissue mapping**: If exosomal transmission drives Braak staging, predict specific spatial patterns of phosphorylated aSyn that correlate with neuronal connectivity; test this using retrograde tracing combined with pathology in human tissue.
### Revised Confidence: **0.65** (−0.17)
The mechanism is biologically plausible but causally unproven. The correlation with Braak staging is descriptive, not mechanistic. Most compelling evidence is correlative.
---
## Hypothesis 2: TREM2-Deficient Microglia
### Weak Links
| Component | Weakness |
|-----------|----------|
| **Effect size** | TREM2 R47H OR ~2-4 for AD risk; this modest effect suggests TREM2 dysfunction is a risk amplifier, not a primary driver |
| **Microglial heterogeneity** | plaque-associated microglia represent a specific subpopulation; systemic TREM2 modulation may affect multiple populations differently |
| **Bidirectional complexity** | TREM2 deletion shows both protective and deleterious effects depending on context and timing |
### Counter-Evidence
1. **Paradoxical neuroprotection**: Some studies report that TREM2 deficiency or haploinsufficiency protects against excitotoxicity and certain viral infections, suggesting microglial TREM2 may amplify neuroinflammation in some contexts.
2. **Timing-dependent effects**: Early TREM2 activation may be beneficial for plaque clearance, but later-stage TREM2 signaling may promote neurodegeneration through cytokine release—suggesting a therapeutic window that may be missed in trials.
3. **TREM2 agonist mixed results**: While preclinical AL002c data were promising, early-phase human trials showed limited CNS target engagement and biomarker effects.
4. **Species differences**: Mouse TREM2 has different ligand affinities and signaling properties than human TREM2; rodent models may overestimate therapeutic potential.
### Falsifying Experiments
1. **Late-stage intervention**: Most studies test TREM2 modulators early. Administer AL002c or similar agonists in 5xFAD mice at 12 months (established plaques); if pathology cannot be reversed, the hypothesis overstates therapeutic potential.
2. **Microglia depletion controls**: Use CSF1R antagonists to deplete microglia entirely, then test whether reintroducing TREM2-deficient vs. wild-type microglia differentially affects plaque burden—isolating TREM2's cell-autonomous role.
3. **Human genetics direction**: If TREM2 loss-of-function causes AD, identify individuals with complete TREM2 deficiency (not just risk variants); assess whether they develop early-onset AD at rates higher than predicted.
### Revised Confidence: **0.78** (−0.10)
This is among the better-supported hypotheses with strong human genetics, but effect sizes and timing complexity warrant more caution than the original 0.88 score.
---
## Hypothesis 3: Mitophagy Induction
### Weak Links
| Component | Weakness |
|-----------|----------|
| **Sporadic vs. familial gap** | PINK1/PARKIN mutations cause familial PD; assuming identical mechanisms in sporadic PD lacks direct evidence |
| **Mitophagy is not uniformly protective** | Excessive mitophagy can be detrimental; basal mitophagy is essential for mitochondrial quality control |
| **USP30 specificity** | USP30 inhibition enhances mitophagy but may have off-target effects on other DUBs |
### Counter-Evidence
1. **PINK1 beyond mitophagy**: PINK1 has kinase substrates beyond parkin and mitophagy regulators; some PINK1 phenotypes may be mitophagy-independent.
2. **Failed neuroprotection in humans**: Despite strong preclinical data, no mitophagy-enhancing therapy has succeeded in PD clinical trials.
3. **Compensatory mechanisms**: Cells may upregulate alternative mitophagy pathways (e.g., FUNDC1, BNIP3) when PINK1/PARKIN is impaired, limiting therapeutic potential of USP30 inhibitors.
4. **McWilliams et al. methodology**: In vivo mitophagy reporters (mito-QC) show basal mitophagy rates in Drosophila; translating these findings to mammalian neurons and human disease requires validation.
### Falsifying Experiments
1. **Sporadic PD tissue validation**: Test whether markers of impaired mitophagy (accumulated depolarized mitochondria, decreased parkin translocation) are present in sporadic PD substantia nigra—not just familial cases.
2. **USP30 inhibitor comprehensive profiling**: Test whether GSK2578215A analogs have off-target effects on related DUBs (USP10, USP15) and whether any neuroprotection persists with selective USP30 knockdown.
3. **Temporal intervention**: Block mitophagy enhancement after neurodegeneration is established; if neurons cannot be rescued, the hypothesis is insufficient for late-stage disease.
### Revised Confidence: **0.62** (−0.14)
The familial-to-sporadic extrapolation is a significant leap. Preclinical promise has not translated, which should lower confidence despite mechanistic plausibility.
---
## Hypothesis 4: C9orf72 Nucleocytoplasmic Transport
### Weak Links
| Component | Weakness |
|-----------|----------|
| **DPR as cause vs. consequence** | DPR accumulation may be a downstream marker of neuronal dysfunction rather than a primary driver |
| **Non-cell-autonomous effects** | C9orf72 is expressed in microglia and lymphocytes; pathology may originate outside the nervous system |
| **Transportin mislocalization non-specificity** | Similar findings in Huntington's disease and other conditions; may represent a general dying-neuron signature |
### Counter-Evidence
1. **Variable penetrance**: C9orf72 expansions show age-dependent penetrance but incomplete penetrance even in monozygotic twins—suggesting modifiers that may act independently of DPR accumulation.
2. **DPR toxicity disconnect**: In some models, DPR toxicity does not correlate with expansion size or DPR levels; poly-GA inclusions (most abundant DPR) show minimal correlation with disease severity.
3. **KPT-276 off-target concerns**: Nuclear export inhibitors have multiple cellular targets; apparent rescue of nuclear transport may involve general transcriptional normalization rather than specific NUP restoration.
4. **Alternative C9orf72 mechanisms**: C9orf72 loss-of-function, G-quadruplex RNA foci, and tidal RNA expression are additional pathogenic mechanisms that may act independently of DPR effects.
### Falsifying Experiments
1. **Prevent DPR production without affecting expression**: Use antisense oligonucleotides to selectively block DPR translation while preserving C9orf72 mRNA levels; test whether this is sufficient to prevent neuronal dysfunction independent of C9orf72 knockdown effects.
2. **Human tissue dose-response**: Map whether DPR accumulation correlates with nuclear pore density loss and transport impairment in a graded manner across asymptomatic expansion carriers vs. symptomatic patients.
3. **NUP mutations as controls**: If NUP dysfunction is primary, NUP gene variants should modify disease severity; test this in patient cohorts.
### Revised Confidence: **0.72** (−0.13)
Strong mechanistic evidence but causality remains unclear. The hypothesis has generated promising therapeutic candidates but the multiple pathogenic mechanisms in C9orf72 make it likely incomplete.
---
## Hypothesis 5: LCN2 Astrocyte Toxicity
### Weak Links
| Component | Weakness |
|-----------|----------|
| **LCN2R identity** | The "LCN2R" receptor remains poorly characterized; some proposed receptors (24p3R, LCN2R) have questionable specificity |
| **Ferroptosis in AD unproven** | While ferroptosis is established in some contexts, direct evidence for iron-dependent synaptic loss in AD is limited |
| **Human genetics absent** | No common LCN2 variants are associated with AD risk in GWAS |
### Counter-Evidence
1. **LCN2 elevation may be adaptive**: LCN2 is an acute-phase reactant upregulated in response to inflammation; its elevation may represent a protective response rather than a toxin.
2. **Ferroptosis evidence inconsistent**: While Zhou et al. provide compelling data, many ferroptosis studies use体外 models with high iron concentrations not representative of brain interstitial fluid.
3. **Astrocyte heterogeneity**: Not all astrocytes express LCN2; the hypothesis requires specification of which astrocyte subpopulations are relevant.
4. **Weak GWAS support**: LCN2 and related iron metabolism genes show weak or inconsistent associations with AD in large GWAS meta-analyses.
### Falsifying Experiments
1. **Definitively identify LCN2R**: Perform rigorous ligand-receptor binding studies (surface plasmon resonance, crystallography) to identify the authentic LCN2 receptor, then test whether LCN2 binding activates iron-dependent toxicity through this receptor.
2. **Iron chelation in human AD**: If ferroptosis is relevant, iron chelation (deferoxamine, deferasirox) should show cognitive benefit in AD trials; current trials show limited efficacy.
3. **LCN2 knockout comprehensive phenotyping**: Beyond amyloid models, test whether LCN2 knockout affects aging-related cognitive decline in wild-type mice; if no phenotype, the target's importance is limited.
### Revised Confidence: **0.48** (−0.23)
This hypothesis has the weakest evidentiary foundation among the seven. The poor human genetics support, unclear receptor identity, and inconsistent ferroptosis evidence warrant substantial demotion.
---
## Hypothesis 6: c-Abl in PD
### Weak Links
| Component | Weakness |
|-----------|----------|
| **aSyn Y39 vs. S129** | Phosphorylation at S129 is the predominant modification in human synucleinopathies; Y39 phosphorylation is less abundant and its role in aggregation is contested |
| **Nilotinib off-target effects** | Nilotinib is a potent BCR-ABL inhibitor; apparent CNS effects may involve off-target kinases (DDR1, DDR2) rather than c-Abl |
| **c-Abl activation in sporadic PD** | Direct evidence of c-Abl activation in sporadic PD patient tissue is inconsistent |
### Counter-Evidence
1. **Clinical trial disappointments**: The Ko et al. (2020) trial showed nilotinib reduced CSF α-syn but did not demonstrate clinical efficacy (UPDRS improvement); the primary endpoint was not met.
2. **BBB penetration争议**: Earlier claims that nilotinib "crosses the BBB" were based on limited pharmacokinetic data; later studies questioned whether therapeutic concentrations reach the substantia nigra.
3. **Alternative nilotinib mechanisms**: Nilotinib inhibits multiple kinases and may enhance autophagy through pathways independent of c-Abl; the mechanism cannot be attributed to c-Abl inhibition.
4. **Mahul-Mellier specificity**: While this study provides compelling Y39 phosphorylation data, the field has not converged on Y39 as the critical modification compared to S129.
### Fals